139 related articles for article (PubMed ID: 7955816)
1. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity.
Hamelin BA; Xu K; Vallé F; Manseau L; Richer M; LeBel M
Clin Pharmacol Ther; 1994 Nov; 56(5):521-9. PubMed ID: 7955816
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
3. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
Krul C; Hageman G
J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
[TBL] [Abstract][Full Text] [Related]
4. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
5. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis.
Kennedy MJ; Scripture CD; Kashuba AD; Scott CS; Gaedigk A; Kearns GL
Clin Pharmacol Ther; 2004 Mar; 75(3):163-71. PubMed ID: 15001967
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
[TBL] [Abstract][Full Text] [Related]
7. Caffeine metabolism before and after liver transplantation.
Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
[TBL] [Abstract][Full Text] [Related]
8. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
9. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
Relling MV; Lin JS; Ayers GD; Evans WE
Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
11. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
[TBL] [Abstract][Full Text] [Related]
12. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.
Vistisen K; Poulsen HE; Loft S
Carcinogenesis; 1992 Sep; 13(9):1561-8. PubMed ID: 1394840
[TBL] [Abstract][Full Text] [Related]
13. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
15. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
Rasmussen BB; Brøsen K
Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
[TBL] [Abstract][Full Text] [Related]
16. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.
Kalow W; Tang BK
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):508-19. PubMed ID: 1934864
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.
Bechtel YC; Haffen E; Lelouët H; Brientini MP; Paintaud G; Miguet JP; Bechtel PR
Int J Clin Pharmacol Ther; 2000 Oct; 38(10):467-75. PubMed ID: 11073287
[TBL] [Abstract][Full Text] [Related]
18. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.
Kennedy MJ; Abdel-Rahman SM; Kashuba AD; Leeder JS
J Clin Pharmacol; 2004 Jul; 44(7):708-14. PubMed ID: 15199075
[TBL] [Abstract][Full Text] [Related]
19. Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients.
Elkiran T; Harputluoglu H; Yasar U; Babaoglu MO; Dincel AK; Altundag K; Ozisik Y; Guler N; Bozkurt A
Methods Find Exp Clin Pharmacol; 2007; 29(1):27-32. PubMed ID: 17344941
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole treatment does not affect the metabolism of caffeine.
Andersson T; Bergstrand R; Cederberg C; Eriksson S; Lagerström PO; Skånberg I
Gastroenterology; 1991 Oct; 101(4):943-7. PubMed ID: 1889718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
